National Institute on Drug Abuse; Notice of Closed Meetings, 52519-52520 [2019-21459]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 84, No. 191 / Wednesday, October 2, 2019 / Notices
Contact Person: Pat Manos, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5200,
MSC 7846, Bethesda, MD 20892, 301–408–
9866, manospa@csr.nih.gov.
Name of Committee: Oncology 1—Basic
Translational Integrated Review Group;
Cancer Molecular Pathobiology Study
Section.
Date: October 31–November 1, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Manzoor Zarger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6208,
MSC 7804, Bethesda, MD 20892, (301) 435–
2477, zargerma@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Immunology: Fellowship.
Date: October 31–November 1, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Liying Guo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4016F,
Bethesda, MD 20892, 301–435–0908, lguo@
mail.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Synapses, Cytoskeleton and
Trafficking Study Section.
Date: October 31–November 1, 2019.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Radisson Plaza Lord Baltimore, 20
West Baltimore Street, Baltimore, MD 21201.
Contact Person: Christine A. Piggee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4186,
MSC 7850, Bethesda, MD 20892, 301–435–
0657, christine.piggee@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cell Signaling, Development and
Aging.
Date: October 31, 2019.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: David Balasundaram,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
VerDate Sep<11>2014
16:42 Oct 01, 2019
Jkt 250001
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 26, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–21393 Filed 10–1–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploring Epigenomic or Non-Coding RNA
Regulation in the Development,
Maintenance, or Treatment of Chronic Pain
(R61/R33 Clinical Trial Optional).
Date: October 4, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 95509529, 301–
827–4471, Bethesda, MD 20892, ramadanir@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; DeviceBased Treatments for Substance Use
Disorders (UG3/UH3) (Clinical Trial
Optional).
Date: October 8, 2019.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
52519
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4242, MSC 9550, Bethesda,
MD 20892, 301–827–5833, ivan.navarro@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
National Drug Early Warning System
Coordinating Center (U01 Clinical Trial
Optional).
Date: October 21, 2019.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Rapid
Assessment of Drug Abuse: Smart City Tools.
Date: October 24, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug, Abuse National Institutes
of Health, DHHS, 6001 Executive Blvd. Room
4235 MSC 9550, Bethesda, MD 20892–9550,
301–827–5819, gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Providing Research Education Experiences to
Enhance Diversity in the Next Generation of
Substance Abuse and Addiction Scientists
(R25—Clinical Trials Not Allowed).
Date: October 28, 2019.
Time: 8:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Alcohol
E:\FR\FM\02OCN1.SGM
02OCN1
khammond on DSKJM1Z7X2PROD with NOTICES
52520
Federal Register / Vol. 84, No. 191 / Wednesday, October 2, 2019 / Notices
and Other Substance Use Research Education
Programs for Health Professionals and NIDA
Research Education Program for Clinical
Researchers and Clinicians.
Date: October 28, 2019.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550 Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploiting Omics Assays to Investigate
Molecular Regulation of Persistent HIV in
Individuals with Substance Use Disorder
(R61/R33 Clinical Trial Optional).
Date: October 31, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 95509529, 301–
827–4471, Bethesda, MD 20892, ramadanir@
mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Digital
Health Technologies to Address the Social
Determinants of Health in context of
Substance Use Disorders (SUD).
Date: November 1, 2019.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd. Room
4235 MSC 9550, Bethesda, MD 20892–9550,
301–827–5819, gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; R13
Conference Grant Review.
Date: December 9–10, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Yvonne Owens Ferguson,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
VerDate Sep<11>2014
16:42 Oct 01, 2019
Jkt 250001
Drug Abuse, NIH/DHHS, 6001 Executive
Blvd., Rm. 4234, Bethesda, MD 20892, 301–
402–7371, yvonne.ferguson@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 27, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2019–21459 Filed 10–1–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biomedical
Informatics, Library and Data Sciences
Review Committee.
Date: March 5–6, 2020.
Time: March 5, 2020, 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Hyatt, 1 Metro Center,
Bethesda, MD 20814.
Time: March 6, 2020, 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Contact Person: Zoe E. Huang, MD, Chief
Scientific Review Officer, Scientific Review
Office, Extramural Programs, National
Library of Medicine, NIH, 6705 Rockledge
Drive, Suite 301, Bethesda, MD 20892–7968,
301–594–4937, huangz@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: September 26, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–21394 Filed 10–1–19; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Limited Competition: Continuation of the
Center for Genomic Studies on Mental
Disorders (U24).
Date: November 7, 2019.
Time: 11:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Vinod Charles, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6151, MSC 9606,
Bethesda, MD 20892–9606, 301–443–1606,
charlesvi@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
NIMH Pathway to Independence Awards
(K99/R00).
Date: November 7, 2019.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: David W. Miller, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6140, MSC 9608,
Bethesda, MD 20892–9608, 301–443–9734,
millerda@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
BRAIN Initiative: Ruth L. Kirschstein NRSA
Individual Postdoctoral Fellowship (F32).
Date: November 22, 2019.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852.
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 84, Number 191 (Wednesday, October 2, 2019)]
[Notices]
[Pages 52519-52520]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21459]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploring Epigenomic or Non-Coding RNA Regulation in
the Development, Maintenance, or Treatment of Chronic Pain (R61/R33
Clinical Trial Optional).
Date: October 4, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 95509529, 301-827-4471,
Bethesda, MD 20892, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Device-Based Treatments for Substance Use Disorders
(UG3/UH3) (Clinical Trial Optional).
Date: October 8, 2019.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892,
301-827-5833, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; National Drug Early Warning System Coordinating
Center (U01 Clinical Trial Optional).
Date: October 21, 2019.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse,
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Rapid Assessment of Drug Abuse: Smart City Tools.
Date: October 24, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug, Abuse National Institutes of Health, DHHS, 6001 Executive
Blvd. Room 4235 MSC 9550, Bethesda, MD 20892-9550, 301-827-5819,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Providing Research Education Experiences to Enhance
Diversity in the Next Generation of Substance Abuse and Addiction
Scientists (R25--Clinical Trials Not Allowed).
Date: October 28, 2019.
Time: 8:30 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse,
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Alcohol
[[Page 52520]]
and Other Substance Use Research Education Programs for Health
Professionals and NIDA Research Education Program for Clinical
Researchers and Clinicians.
Date: October 28, 2019.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse,
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550 Bethesda, MD 20892, 301-402-6020, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploiting Omics Assays to Investigate Molecular
Regulation of Persistent HIV in Individuals with Substance Use
Disorder (R61/R33 Clinical Trial Optional).
Date: October 31, 2019.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 95509529, 301-827-4471,
Bethesda, MD 20892, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Digital Health Technologies to Address the Social
Determinants of Health in context of Substance Use Disorders (SUD).
Date: November 1, 2019.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd. Room 4235 MSC 9550, Bethesda, MD 20892-9550, 301-827-5819,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; R13 Conference Grant Review.
Date: December 9-10, 2019.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Yvonne Owens Ferguson, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH/DHHS,
6001 Executive Blvd., Rm. 4234, Bethesda, MD 20892, 301-402-7371,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: September 27, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-21459 Filed 10-1-19; 8:45 am]
BILLING CODE 4140-01-P
